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Vaccinea b s t r a c t
Persistence of immune memory in humans is a crucial yet poorly understood aspect of immunology. Here
we have studied the effect of Puumala hantavirus infection on unrelated, pre-existing immune memory
by studying T cell- and antibody responses against toxoid vaccine antigens of diphtheria, tetanus and per-
tussis in a cohort of 45 patients. We found that tetanus- and pertussis -specific IgG concentrations elevate
during acute Puumala virus infection. Increase in vaccine IgG was associated with proliferation of
heterologous T cells. Interestingly, increases in tetanus-specific IgG persisted a year after the infection
while pertussis-specific IgG declined rapidly; a difference in IgG kinetics resembling the difference seen
after vaccination against tetanus and pertussis. These results suggest that persistence of immune mem-
ory is facilitated by heterologous boosting of old memory during memory formation against newly
encountered antigens. They also show that different toxoid antigens may be treated differently. Our study
gives new insight into how immune memory formation may alter pre-existing immune memory, and also
shows that heterologous immunity may have an impact on vaccination outcomes.
 2021 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction tified particularly in rodents and between viral antigens [5], but itsImmunological memory allows the immune system to generate
rapid and effective responses to previously encountered antigens;
a function necessary for gaining immunity against pathogens [1].
Classically, immunological memory was thought to be dependent
on heterogeneous memory T and B cell populations, but this defi-
nition of immunological memory has recently been challenged
by the discovery of non-antigen-specific memory dependent of
epigenetic programming in innate immune cells [2]. Furthermore,
while memory cell mediated immunological memory is in princi-
ple antigen-specific, stimulation of the immune system can
amplify unrelated pre-existing memory in a phenomenon known
as heterologous immunity [3,4]. This phenomenon has been iden-significance in humans remains unclear. Activation of heterologous
bystander memory cells can be the result of T cell cross-reactivity
when the antigen epitopes have close similarity [6]. Another sug-
gested pathway for bystander activation is through production of
cytokines, which would not require cross-reactivity [7]. Here we
have addressed the phenomenon of heterologous immunity in
patients infected by the zoonotic Puumala virus.
Puumala virus (PUUV) is a Hantavirus endemic to Europe,
which is carried and spread by its reservoir host, the bank vole
(Myodes glareolus) [8,9]. PUUV is the cause of a zoonotic illness
known as nephropathia epidemica (NE), a hemorrhagic fever with
renal syndrome [9,10]. Transmission of PUUV occurs through
inhalation of aerosols containing bank vole excreta or secreta [9],
but infected individuals are not infectious, except perhaps through
blood contact [9,11]. Acute PUUV infection induces a strong T cell
response, in which CD8+ T cells are particularly numerous [12].
Viral load in PUUV-infected patients rises after disease onset,
reaching its peak on average 5 days after the occurrence of first
symptoms. Viral load declines after the 7th day, leaving most
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onset of symptoms. Most patients are completely clear of PUUV
after the 16th day after symptom debut [12], but viraemia may
in cases of severe disease progression persist at least 30 days
post-infection [13]. Effector T cell response to PUUV is mediated
by CD8+ T cells. Proliferation of CD8+ T cells is high when the viral
load peaks: over 50% of CD8+ T cells are dividing cells on day 6
after symptom debut [12].
PUUV infection has been reported to increase the number of T
cells reactive against Epstein-Barr virus (EBV), a virus of the her-
pesviridae -family [14]. However, given the fact that EBV produces
a persistent latent infection [15], it is not known, whether these
PUUV-induced T cell responses to EBV depend on reappearance
and new contact with EBV antigens. Memory responses against
EBV could therefore be explained by reactivation of persistent
EBV, and heterologous memory responses to non-persistent patho-
gens may not follow a similar pattern. It is therefore of consider-
able importance, also in terms of clinical practice and
vaccinations, to understand how unrelated infections impact pre-
existing immunological memory to non-persisting antigens.2. Materials and methods
2.1. Patients and ethics
Patients presented with NE, diagnosed either by positive rapid
anti-PUUV IgM test with a specificity of 99% [16] (three patients,
all of whom were included in this study), or by a clinically vali-
dated serological assay at Tampere University Hospital (Tampere,
Finland) between January 2005 and February 2009. Blood and
urine samples were obtained at presentation (d0), and at control
visits around 2 weeks (d14) and 12 months later (1y). Forty-five
of the original 56 patients were available for sampling both at
2 weeks and 12 months later and were thus included. The median
age of the patients included was 43 years, and the distribution was
22–73 years. Nineteen patients were female. Eight patients had an
underlying medical condition (hypertension n = 5; asthma, epi-
lepsy, rheumatic disease n = 1 each); these patients were not iden-
tifiable as outliers in our analysis. No individual data on
vaccination history was available for any of the patients. Serum
samples were stored in 70 C until use. Plasma albumin and urine
albumin- and creatinine concentrations were determined at the
University of Massachusetts Memorial HealthCare Hospital Labs
using standard clinical laboratory methods. The study was per-
formed according to the principles of the Declaration of Helsinki.
All patients gave a written, informed consent. The study was
approved by the ethics committees of the Helsinki University
Hospital and the Tampere University Hospital (study protocol
R04180).2.2. Analysis of antibody concentrations with ELISA
Concentrations of total IgG and IgG specific to pertussis, tetanus
and diphtheria toxoids (PT, TT and DT, respectively) were mea-
sured using enzyme-linked immunosorbent assays (ELISA). Human
IgG total ELISA Ready-SET-Go! kit (88–50550) by eBioscience, Anti-
Bordetella pertussis toxin (PT) IgG ELISA kit (ab178634) by Abcam,
Anti-Tetanus Toxoid ELISA (IgG) kit by Euroimmun (EI 2060–9601
G), and Novagnost Diphtheria 5 S IgG kit by Siemens Healthcare
Diagnostics were used for measuring total IgG, and PT-, TT-, and
DT-specific IgG, respectively. For total IgG-, and TT- and DT -IgG-
determinations, wells were washed using Nunc-Immuno wash 8
plate washer and in-house PBS-Tween washing buffer. For PT-IgG
determinations, wells were washed manually with a pipet using
the washing buffer included in the kit. The absorbances were read1819at 450 nm using BMG FLUOstar OPTIMA Microplate Reader (BMG
Labtech).
2.3. Proliferation of vaccine-specific T cells
T cell stimulation was done as previously described [17].
Monocyte-derived dendritic cells were generated from the blood
of 10 patients and used as antigen-presenting cells to activate T
cells in vitro. The blood samples for the generation of antigen-
presenting cells were drawn a minimum of 1 year after the acute
PUUV infection. Peripheral blood mononuclear cells were isolated
by Ficoll-Paque (GE Lifesciences, Buckinghamshire, UK) gradient
centrifugation and cryopreserved at 134 C with the CTL-Cryo
ABC Media kit (CTL, Shaker Heights, OH, USA), according to manu-
facturer’s instructions. Samples were immunomagnetically
depleted of CD3+ cells using anti-human CD3 mAb (Immunotools,
Friesoythe, Germany) and Dynabeads Pan Mouse IgG beads (Invit-
rogen, Carlsbad, CA, USA), according to manufacturer’s instruc-
tions. The remaining cells were labeled with CellVue (CellVue
Claret Far Red Fluorescent Cell Linker kit, Sigma-Aldrich, St. Louis,
MO, USA) and enriched for monocytes by allowing adhesion to cul-
ture plates. Cells were cultured in RPMI medium with 10% human
AB serum, recombinant IL-4 at 20 ng/ml (ImmunoTools) and GM-
CSF at 10 ng/ml (ImmunoTools), to achieve dendritic cell differen-
tiation. Some of the cultures were simultaneously loaded with vac-
cine antigens, each at 5 lg/ml: tetanus toxoid, diphtheria toxoid
(both from the Finnish National Institute for Health and Welfare),
and m. bovis purified protein derivative (Statens Serum Institut,
Copenhagen, Denmark). The cells were activated after an overnight
culture by using LPS (Sigma-Aldrich) at 1lg/ml, after which the
cells were again cultured overnight. The cells were washed, and
the maturation to dendritic cells was confirmed by flow cytometric
analysis of expression of HLA-DR-PE, CD11c-APC (both from BD
Biosciences) and CD80-FITC (ImmunoTools). 1x106 stimulator cells
were supplemented at 1 ml of RPMI medium with human AB-
serum and recombinant IL-2 (ImmunoTools) at 25 ng/ml and
mixed with 1x 106 autologous responder cells labeled with car-
boxyfluorescein succinimidyl ester (CFSE) at a concentration of
1 mM (CellTrace CFSE Cell Proliferation Kit, Invitrogen), according
to manufacturer’s instructions. The cells were cultured for four
days, after which cells were stained with CD4-APC/Cy7 (BD Bio-
sciences, San Jose, CA, US). Flow cytometry was performed by using
the Cyan instrument (Beckman Coulter, Brea, CA, USA). Prolifera-
tion was assessed by excluding the CellVue-positive stimulator
cells and measuring CFSE dilution in the CD4-positive responder
cells. The negative control values were subtracted from the
antigen-stimulated values to obtain net proliferative values. Flow
cytometry data was analyzed using the FlowJo software (TreeStar,
Ashland, OR, USA).
2.4. Statistics
Statistical analysis was done using the SPSS software (SPSS Inc.).
The data are shown as mean ± SD. P-values for differences between
groups were calculated using the Wilcoxon signed-rank test. Cor-
relations were calculated as Spearman’s rank correlation coeffi-
cient (rho). The limit for statistical significance was 0.05.3. Results
3.1. Heterologous T cell responses
Most vaccines are by definition administered at discrete time
points and are not likely to persist for prolonged periods of time.
To analyze the impact of acute PUUV infection on pre-existing T
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cohort of 10 patients at the time of presentation (d0), at d14, and
at 1y after the acute phase. As antigens to stimulate the T cells
we used a mixture of protein purified derivative of the Mycobac-
terium bovis vaccine strain (Bacillus Calmette-Guerin), tetanus
and diphtheria toxoid. These antigens are present in vaccines,
which are administered to effectively all Finns, and the patients
were therefore expected to have underlying T cell immunity to
these antigens. We did not have individualized data on the vacci-
nation history of the patients.
At presentation and at d14 CD4 +T cells from all but one patient
had a positive rate of proliferation in response to PUUV N-protein.
At presentation, seven patients also showed a slight positive rate to
the vaccine antigens (Fig. 1.), but the responses were generally low
(mean ± SD 0.6 ± 0.7%) and significantly lower than the N-specific
responses (8.4 ± 6.8%, p < 0.01). At d14, nine patients showed a pos-
itive response to the vaccine antigens, and in all nine it was higher
than at presentation. There was also no longer a significant differ-
ence between the responses to N-protein and the vaccine antigens
(data not shown). The increased vaccine responses persisted also
1 year after the acute phase in nine out of ten patients, suggesting
that the cell-mediated responses to vaccine antigens were either
suppressed at d0, or the acute PUUV infection boosted also unre-
lated responses.3.2. Anti-pertussis and anti-tetanus IgG kinetics during acute PUUV
infection and follow-up
To gain a more detailed view of the heterologous boosting of
vaccine-specific memory during acute PUUV infection we analyzed
humoral immunity against three structurally similar vaccine anti-
gens: tetanus-, diphtheria- and pertussis toxoids. In Finland these
antigens are usually combined in a single booster vaccine, and thus
the vaccination history for all three antigens should be in broad
terms similar. Of particular interest is the fact that the duration
of protective immunity to the three toxoids is quite different.
Immunity to tetanus and diphtheria persists for decades, whereas
pertussis immunity wanes in a few years.Fig. 1. Proliferation of vaccine antigen -stimulated CD4+ T cells during acute PUUV
infection. The cells were stimulated with a mixture of TT, DT and M. bovis purified
protein derivative and the background-subtracted net frequency of proliferating
CD4+ is shown at 3 different time points: the first day of hospitalization (d0),
14 days (d14) and 1 year (1y) after hospitalization. The mean ± SD level of
backgound proliferation was 2.5 ± 1.7% at d0, 3.4 ± 3.6% at d14 and 4.7 ± 3.0% at 1y.
Patients are indicated by connected circles. The fraction of proliferating CD4 +T cells
is shown on the y-axis as percentage. Statistical significance of difference between
time points is indicated by symbols * (p < 0, 05), ** (p < 0, 01), and ns. (Not
statistically significant).
1820To analyze the effect of acute PUUV infection on IgG antibodies
specific to pertussis-, tetanus- and diphtheria toxoids (PT, TT and
DT, respectively), we compared antibody levels at presentation
(d0), 2 weeks after presentation (d14), and one year after presenta-
tion (1y) in a cohort of 45 patients with a serologically confirmed
PUUV infection. The PUUV-specific serological status of the
patients was determined at 0–4 days after presentation. TT-, DT-
and PT -specific IgG antibodies were quantified from plasma sam-
ples using enzyme-linked immunoassays (ELISA). PT- and TT -
specific IgG levels increased significantly between d0 and d14
(Fig. 2; p < 0.001 for PT, p = 0.009 for TT). No statistically significant
change was found in the DT-specific IgG levels (Supplemental
Fig. S1), and these responses were not analyzed further. There
was also no significant change in the total IgG levels (Supplemental
Fig. S2). Surprisingly, whereas the increased TT-specific IgG levels
remained stable at the 1y time-point, the PT-specific IgG levels
already showed a significant decline (p < 0.001).Fig. 2. Serum anti-pertussis and anti-tetanus IgG levels during acute PUUV
infection and one-year follow-up. IgG levels are shown on the y-axes as absorbance
for TT (A) and as concentrations for PT (B). Each patient is indicated by a circle in all
time points. Means and standard deviations are shown by horizontal lines at each
time point. Statistical significance of differences between time points are indicated
by symbols * (p < 0, 05), ** (p < 0, 01), *** (p < 0, 001), and ns. (Not statistically
significant).
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patients had detectable TT antibodies while 4 patients had no mea-
surable PT-specific IgG. We then analyzed separately four sub-
groups of 10 patients: patients with either the highest or lowest
initial PT and TT antibody levels. There was some overlap between
the groups, since each group was determined by either PT- or TT -
specific IgG levels, while disregarding the other antigen. Interest-
ingly, the increase in PT-specific IgG during acute PUUV infectionFig. 3. Vaccine antigen -specific IgG kinetics in patients with highest and lowest baseli
shown in time-points d0, d14 and 1y. (A) and (B), respectively: TT- and PT -specific IgG
respectively: TT- and PT -specific IgG levels of patients with lowest initial TT- and PT -spe
differences between time points is indicated by symbols * (p < 0, 05), ** (p < 0, 01), and
1821was most notable in those patients with already relatively high
antibody levels (Fig. 3). This suggests that, although all patients
had received multiple doses of pertussis vaccine, a persisting and
measurable level of immunity was a prerequisite for heterologous
boosting. In TT-specific responses the trend was less clear, and the
pre-existing IgG levels did not predict the magnitude of increase.
On the average, patients with the highest initial PT-specific IgG
concentrations who received detectable heterologous boosting hadnes. Vaccine antigen -specific IgG levels of four different groups of 10 patients are
levels of patients with highest initial TT- and PT -specific IgG levels. (C) and (D),
cific IgG levels. Patients are indicated by connected circles. Statistical significance of
ns. (Not statistically significant).
Fig. 4. Correlation of vaccine antigen -specific IgG levels with plasma albumin concentrations and urine albumin-creatinine ratios at the time of presentation. PT- and TT-
specific IgG levels were correlated with plasma albumin concentrations (A), total IgG concentrations (B), and urine protein-creatinine ratios (C) measured in the acute phase.
IgG levels are shown on the y axes as concentrations for pertussis toxin and total IgG, and as absorbance coefficients for tetanus toxin. Albumin concentrations, total IgG
concentrations, and albumin-creatinine ratios are shown on the x-axes. Each patient is indicated by a closed circle. N = 25 for A and C, N = 45 for B. Linear regression curves,
correlation coefficients (rho), and statistical significance (ns, not significant) are shown.
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the immunity already showed clear signs of waning. As expected,
the patients with low initial PT antibody levels and little heterolo-
gous boosting had low PT-specific IgG levels in the 1-year control
samples, as well. A similarly rapid fall was not seen in TT-specific
antibodies, and on the average there was no significant difference
between d14 and 1y in either the high or low initial TT-antibody
group. Taken together, these findings show a difference between
baseline immunity to TT and PT, but also suggest that heterologous
boosting has distinct effects on the humoral responses to these two
protein antigens.
We have previously shown that the single best surrogate for NE
severity is the length of hospitalization [18]. To determine whether
the highly variable clinical course of NE affected the heterologous
responses we compared the change in TT- and PT-specific IgG
levels between d0 and d14, and between d14 and 1y with hospital-
ization length, but found no significant correlations (Supplemental
Fig. S3). No further clinical correlations were analyzed.3.3. Excluding the effect of transient albuminuria on antibody
concentrations
NE involves increased vascular permeability and acute kidney
injury involving transient proteinuria [10]. Proteinuria, and also
vascular leakage and acute infection itself may decrease concentra-
tions of plasma proteins. Proteinuria in NE is non-selective, due to
defects in glomerular barrier [19,20]. Low amounts of antibodies
against TT and PT in acute samples in comparison with later time
points could therefore be explained by excretion of protein, includ-
ing antibodies, in the kidneys and blood vessels, or other mecha-
nisms of hypoproteinemia. To exclude the possibility that the
observed increase in TT- and PT-specific antibody levels was due
to the recovery process and thus secondary to general loss of
plasma proteins at the acute phase we compared vaccine antibody
levels to plasma albumin concentrations and total IgG levels (Fig. 4
A and B, respectively). We also measured proteinuria using urine
protein-creatinine ratios and compared the results with vaccine
antibody levels (Fig. 4 C). Plasma albumin concentrations and urine
protein-creatinine ratios were available from 25 patients in our
cohort, while total IgG concentrations were determined of all
included patients. However, no significant correlations were
observed between toxoid antibody levels and plasma albumin,
plasma IgG, or urine protein levels. These data suggest that tran-
sient albuminuria, hypoalbuminemia or hypogammaglobulinemia
had no effect on vaccine antibody levels.4. Discussion
For several reasons, PUUV infection is a promising model to
study the generation and maintenance of immunological memory
in humans during a natural, wild-type infection. PUUV infection
results in a robust generation of CD8+ memory T-cells and
PUUV-specific antibodies after the acute phase of the infection
[14,21], and they have been shown to persist for at least a decade
post-infection [21,22]. Primary infections are diagnosed easily
through detection of PUUV-specific IgM- antibodies [23]. PUUV
neither persists, nor re-infects [9], which makes it a suitable patho-
gen to be used in the study of immunological memory. Further-
more, PUUV infects vascular endothelium, with pathological
consequences such as increased permeability, and it also affects
spleen [9,24,25]. These considerations suggest that blood is likely
to be a relevant tissue for analysis of effector mechanisms in these
patients.
In the present study we show an increase in heterologous CD4
+T cells and TT- and PT -specific IgG concentrations in patient1823serum samples during acute PUUV-infection, with similar kinetics
in the cellular and humoral responses. There are several caveats
concerning the T cell data. First, we only analyzed proliferative
responses, which may not accurately reflect other aspects of T cell
function such as cytokine production. Second, since the cells were
stimulated by a mixture of antigens from several vaccines, we can-
not differentiate the response to individual proteins. Finally, we
cannot rule out activation-induced cell death as a contributing fac-
tor to the lower frequency of responding T cells at presentation
[26], so the results concerning the cellular responses must be con-
sidered preliminary.
However, no such complication pertains to the serological find-
ings, and indeed, clinical validation of protective immunity after
toxoid vaccination is based on measuring IgG levels, which adds
to the relevance of the humoral data. Our data also show that vas-
cular leakage, transient hypogammaglobulinemia or other loss of
serum proteins during the infection did not account for increase
in vaccine-specific antibody concentrations. Therefore, our data
indicate that acute PUUV infection also activates bystander B lym-
phocytes specific to non-persistent antigens, enhancing measur-
ably heterologous memory. Interestingly, whereas TT-specific IgG
remained elevated during the follow-up, PT-specific IgG declined
rapidly.
Since we analyzed vaccine-associated antigens, administration
of these vaccines may have some effect on the data. Patient-
specific data regarding vaccination status were not available for
use in this study, and therefore we cannot analyze the effects of
prior vaccinations on our results. However, vaccination is con-
traindicated during acute febrile disease. The increase in vaccine-
specific immunity during the acute phase is thus highly unlikely
to be caused by specific boosting. At the time of the study, the rec-
ommended interval for tetanus vaccination in Finland was 10 years
[27,28], so approximately 10% of our patients would be expected to
receive a booster during the 1-year follow-up. This may thus con-
tribute to the maintenance of tetanus immunity in some patients,
but overall we observed no further increase during follow-up. In
contrast, pertussis vaccines are mainly administered during child-
hood, while in the adult version of the toxoid vaccine the acellular
pertussis component is usually absent [28]. This may explain, at
least in part, the generally lower baseline immunity to PT. Even
so, the heterologous boosting of PT responses was roughly similar
to that of TT responses.
Due to the nature of our study, we cannot address directly the
mechanism responsible for the heterologous boosting. It is likely
that the boosting takes place in lymphoid tissues, while we only
had access to blood samples. In experimental models, heterologous
immunity has been explained by antigen-specific cross-reactive
mechanisms [29], or non-specific, often cytokine-mediated mech-
anisms [3,30], which are not mutually exclusive. In our setting,
antigen-specific heterologous boosting is unlikely. Tetanus is an
exceedingly rare disease in Finland [31], and natural exposure to
TT is therefore highly unlikely. During the study period annual per-
tussis incidence in Finland ranged from 0.005% to 0.03% [31], so
few if any of our patients are likely to have been infected during
the follow-up. Another possible mechanism for heterologous
memory responses would be T cell cross-reactivity. T cell cross-
reactions to different viruses due to similarities between viral anti-
gens have been reported, and may occur even between viruses
from different families, e.g. influenza virus and hepatitis C virus
[32]. However, there is no published evidence of cross-reactivity
between TT, PT and PUUV antigens, and therefore cytokine-
mediated boosting may be responsible.
Heterologous memory responses witnessed in this study are
mainly related to long-lived plasma cells, since in the absence of
reinfection they are responsible for maintaining plasma IgG levels
against previously encountered pathogens. Bystander activation of
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surface Ig expression is low or absent in plasma cells, cytokines are
likely to play a role. Most notably IL-6, APRIL (a proliferation-
inducing ligand), TNF-alpha and BMCA (B-cell maturation antigen)
have been associated with the maintenance of a microenvironment
that promotes longevity of long-lived plasma cells [33]. Although
poorly understood in humans, changes in this microenvironment
are likely to take place during acute infections, and they could con-
tribute to the augmentation of pre-existing IgG production.
Among other reasons, such as vaccine uptake, the persistent cir-
culation of pertussis infections in most populations has been linked
to the unexpectedly rapid decline in vaccine- and infection-
induced immunity. Whereas vaccine-induced immunity against
tetanus persists for at least 30 years [34], for reasons currently
unknown pertussis vaccine efficacy declines already in 4 years
[35]. Our data identify a novel factor contributing to this difference
between the two pathogens: while both TT and PT-specific
responses were boosted by the natural PUUV infection, only the
TT responses were maintained during the follow-up. It thus seems
that not only revaccinations, but also other forms of boosting have
only a transient effect on the maintenance of pertussis immunity.
This finding was compounded by the generally lower baseline
immunity to PT, as our results showed that without measurable
pre-existing PT antibodies heterologous boosting had little effect.
This study contributes to the discussion on the persistence of
immune memory. CD8+ memory T cells have been reported to per-
sist independently of antigen contact, but the impact of new mem-
ory formation has remained unclear [36,37]. Our results identify
heterologous stimulation of both humoral- and T cell memory to
non-persistent antigens during a natural, wild-type viral infection.
They also suggest that heterologous immunity and its longevity
may have measurable effects on vaccine efficacy in humans, specif-
ically as pertains to the difference between tetanus and pertussis
immunity.Declaration of Competing Interest
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